- Home
- PYN vs COEP Comparison
PYN vs COEP Comparison
Compare PYN & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- COEP
- Stock Information
- Founded
- PYN 2002
- COEP 2017
- Country
- PYN United States
- COEP United States
- Employees
- PYN N/A
- COEP N/A
- Industry
- PYN Investment Managers
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PYN Finance
- COEP Health Care
- Exchange
- PYN Nasdaq
- COEP Nasdaq
- Market Cap
- PYN 30.1M
- COEP 27.4M
- IPO Year
- PYN N/A
- COEP N/A
- Fundamental
- Price
- PYN $5.29
- COEP $9.47
- Analyst Decision
- PYN
- COEP
- Analyst Count
- PYN 0
- COEP 0
- Target Price
- PYN N/A
- COEP N/A
- AVG Volume (30 Days)
- PYN 19.9K
- COEP 38.0K
- Earning Date
- PYN 01-01-0001
- COEP 08-15-2025
- Dividend Yield
- PYN 5.07%
- COEP N/A
- EPS Growth
- PYN N/A
- COEP N/A
- EPS
- PYN N/A
- COEP N/A
- Revenue
- PYN N/A
- COEP $62,874.00
- Revenue This Year
- PYN N/A
- COEP N/A
- Revenue Next Year
- PYN N/A
- COEP N/A
- P/E Ratio
- PYN N/A
- COEP N/A
- Revenue Growth
- PYN N/A
- COEP N/A
- 52 Week Low
- PYN $4.84
- COEP $2.31
- 52 Week High
- PYN $6.60
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- PYN 49.80
- COEP 62.24
- Support Level
- PYN $5.25
- COEP $7.25
- Resistance Level
- PYN $5.37
- COEP $9.90
- Average True Range (ATR)
- PYN 0.10
- COEP 0.63
- MACD
- PYN 0.01
- COEP 0.26
- Stochastic Oscillator
- PYN 9.59
- COEP 85.62
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.